Search results for "Activin A"

showing 6 items of 6 documents

Activin A Signaling Regulates IL13Rα2 Expression to Promote Breast Cancer Metastasis

2019

Metastatic dissemination of cancer cells to distal organs is the major cause of death for patients suffering from the aggressive basal-like breast cancer (BLBC) subtype. Recently, we have shown that interleukin 13 receptor alpha 2 (IL13Rα2) is a critical gene that is overexpressed in a subset of BLBC primary tumors associated with poor distant metastasis-free survival (DMFS) and can promote extravasation and metastasis of breast cancer cells to the lungs. However, the upstream signaling mechanisms that promote aberrant IL13Rα2 expression during tumor progression remain unknown. Driven by our previously published gene expression microarray data derived from a well-characterized cell line mod…

0301 basic medicineCancer ResearchBiologymigrationlcsh:RC254-282MetastasisIL13Rα203 medical and health sciencesbreast cancer0302 clinical medicineBreast cancermedicinemetastasisOriginal ResearchCancerActivin receptorActivin Alcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMetastatic breast cancerPrimary tumor030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisCancer cellCancer researchFrontiers in Oncology
researchProduct

Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report.

2016

This study was directed to assess the clinical impact of the circulating cathepsin L, cystatin C, activin A, and follistatin in breast cancer patients. The serum concentrations of these molecules were determined by immunoenzymatic assays, and their association with some clinico-pathological parameters of breast cancer progression was evaluated. Our results identified cystatin C and activin A as predictive markers for the presence of breast cancer and bone metastasis, respectively. Therefore, these proteins may have a clinical role as circulating biomarkers in the diagnosis and therapeutic monitoring of breast cancer patients.

0301 basic medicineCancer ResearchFollistatinCathepsin LBone NeoplasmsBreast NeoplasmsActivinCathepsin L03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerPreliminary reportmedicineBiomarkers TumorHumansbone metastasiCystatin CNeoplasm Metastasisskin and connective tissue diseasesAgedNeoplasm Stagingbiologybusiness.industryBone metastasisGeneral MedicineMiddle Agedmedicine.diseaseTherapeutic monitoringActivinsActivin a030104 developmental biologyOncologyCystatin CROC Curvetumor markers030220 oncology & carcinogenesisSettore BIO/14 - Farmacologiabiology.proteinCancer researchDisease ProgressionbiomarkerOsteoporosisFemaleNeoplasm Gradingbusinesshormones hormone substitutes and hormone antagonistsFollistatinCancer investigation
researchProduct

Activin and inhibin A in predicting outcome of pregnancies of unknown location after ART

2018

Abstract The aim was to investigate the predictive value of a single serum determination of activin A and inhibin A for classifying pregnancies of unknown location (PUL) after IVF cycles in both own fresh and donated oocytes. A case–control study conducted in a University-affiliated IVF center. Pregnancy outcomes after own fresh oocytes included 12 failing PUL, 12 ectopic pregnancies (EP) and a control group of 24 singleton intrauterine pregnancies (IUP). The same scheme was followed for the oocyte donation recipients. Inhibin A, activin A, β-hCG and Progesterone (P) were determined. In the own fresh oocytes IVF, the AUC for predicting EP vs. f failing PUL were: Activin A: 0.458 and Inhibin…

0301 basic medicineendocrine systemPregnancyInhibin a030219 obstetrics & reproductive medicineEctopic pregnancybusiness.industryActivin and inhibinmedicine.diseasefemale genital diseases and pregnancy complicationsActivin aAndrology03 medical and health sciences030104 developmental biology0302 clinical medicineInduced ovulationOocyte donationMedicineBiomarker (medicine)businessreproductive and urinary physiologyhormones hormone substitutes and hormone antagonistsMedicina Reproductiva y Embriología Clínica
researchProduct

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer

2006

Recent studies have highlighted that Activin A, a member of the transforming growth factor-beta (TGF-beta) superfamily, may be involved in the regulation of osteoblastic activity and in osteoclast differentiation. Therefore, we have investigated the clinical significance of its circulating levels in patients with bone metastasis. Activin A serum concentrations were determined, by a commercially available enzyme-linked immunosorbent assay kit, in 72 patients with breast cancer (BC) or prostatic cancer (PC) with (BM+) or without (BM-) bone metastases, in 15 female patients with age-related osteoporosis (OP), in 20 patients with benign prostatic hypertrophy (BPH) and in 48 registered healthy b…

MaleCancer Researchmedicine.medical_specialtyBone diseaseOsteoporosisProstatic HyperplasiaBone NeoplasmsBreast NeoplasmsActivin A; Benign prostatic hypertrophy; Bone metastasis; Breast cancer; Neoplasm; > Osteoporosis; Prostate cancer; Transforming growth factor ¦Â; Tumor markersSensitivity and SpecificityGastroenterologyProstate cancerBreast cancerBreast cancerOsteoclastInternal medicineBiomarkers TumormedicineHumansAgedAged 80 and overHematologyProstate cancerbusiness.industryOsteoporosiProstatic NeoplasmsBone metastasisCancerGeneral MedicineMiddle AgedActivin ATransforming growth factor ¦Âmedicine.diseaseBenign prostatic hypertrophyActivinsmedicine.anatomical_structureEndocrinologyOncologyBone metastasiTumor markersOsteoporosisNeoplasmFemalebusiness
researchProduct

Activin a and matrix metalloproteinase-2 and -9 blood levels as gauges of bone metastatic spread. In: Tumor microenvironment:Heterotypic interactions.

2006

activin a metallo proteinase-2 bone
researchProduct

Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in women with idiopathic premature ovarian failure.

2003

Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in 30 women with idiopathic premature ovarian failure (POF), 30 postmenopausal women, and 30 age-matched fertile women were determined. Women with POF showed low levels of inhibin A and inhibin B, but not of activin A, whereas the levels of pro-alphaC were significantly higher than in postmenopausal women. Thus, the circulating level of pro-alphaC could be a marker for assessing residual ovarian function in women with POF.

endocrine systemInhibin amedicine.medical_specialtyendocrine system diseasesPrimary Ovarian InsufficiencyAndrologyOvarian functionInternal medicineMedicineHumansInhibinsProtein Precursorsreproductive and urinary physiologyInhibin bPostmenopausal womenbusiness.industryObstetrics and Gynecologyfemale genital diseases and pregnancy complicationsActivin aPostmenopauseIdiopathic premature ovarian failureEndocrinologyReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct